News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Hedge Fund Wants Actelion Ltd. CEO To Quit
February 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - Actelion (ATLN.VX) shares rose 3.5 percent on Friday after hedge fund shareholder Elliott Advisors called for its chairman and chief executive to resign from the board in a push for a sale of the Swiss biotech firm.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Drug pricing
White House Strikes GLP-1 Pricing Deal With Lilly, Novo
November 6, 2025
·
3 min read
·
Annalee Armstrong
Earnings
Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing
November 6, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
AstraZeneca Builds Obesity Pipeline On ‘Medical Aspect,’ Not Aesthetics
November 6, 2025
·
2 min read
·
Tristan Manalac
Legal
Delaware Court Denies Pfizer’s Bid To Block Novo-Metsera Deal
November 6, 2025
·
2 min read
·
Tristan Manalac
